Menu
GWAS Study

Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD.

Grunin M, Beykin G, Rahmani E et al.

32106291 PubMed ID
GWAS Study Type
295 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

GM
Grunin M
BG
Beykin G
RE
Rahmani E
SR
Schweiger R
BG
Barel G
HS
Hagbi-Levi S
ES
Elbaz-Hayoun S
RB
Rinsky B
GM
Ganiel M
CS
Carmi S
HE
Halperin E
CI
Chowers I
Chapter II

Abstract

Summary of the research findings

Purpose: Anti-vascular endothelial growth factor (VEGF) therapy for neovascular AMD (nvAMD) obtains a variable outcome. We performed a genome-wide association study for anti-VEGF treatment response in nvAMD to identify variants potentially underlying such a variable outcome.

187 Israeli ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

295
Total Participants
GWAS
Study Type
Yes
Replicated
108 Israeli ancestry individuals
Replication Participants
European, Greater Middle Eastern (Middle Eastern, North African or Persian)
Ancestry
Israel
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.